These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3928677)

  • 1. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation.
    Barnes RB; Lobo RA
    J Clin Endocrinol Metab; 1985 Oct; 61(4):779-82. PubMed ID: 3928677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea.
    Quigley ME; Sheehan KL; Casper RF; Yen SS
    J Clin Endocrinol Metab; 1980 May; 50(5):949-54. PubMed ID: 6246138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dopamine and metoclopramide in polycystic ovary syndrome.
    Barnes RB; Mileikowsky GN; Cha KY; Spencer CA; Lobo RA
    J Clin Endocrinol Metab; 1986 Aug; 63(2):506-9. PubMed ID: 3722335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Perić LA
    J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral dopamine metabolism in polycystic ovary syndrome.
    Barnes RB; Artal R; Lobo RA
    Obstet Gynecol; 1987 Aug; 70(2):153-6. PubMed ID: 3601275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of the endogenous opioid system in the pathogenesis of polycystic ovary syndrome: the altered neuroendocrine regulation of GnRH-LH is corrected after clomiphene therapy].
    Barletta C; Vagiri D; Scavo D
    Minerva Endocrinol; 1992; 17(3):107-19. PubMed ID: 1298870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Perić LA
    J Endocrinol Invest; 1987 Aug; 10(4):389-95. PubMed ID: 3119696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactin response after gonadotropin-releasing hormone in the polycystic ovary syndrome.
    Shoupe D; Lobo RA
    Fertil Steril; 1985 Apr; 43(4):549-53. PubMed ID: 3921411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin release in polycystic ovary.
    Falaschi P; del Pozo E; Rocco A; Toscano V; Petrangeli E; Pompei P; Frajese G
    Obstet Gynecol; 1980 May; 55(5):579-82. PubMed ID: 6768043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin levels in the polycystic ovary syndrome.
    Milewicz A
    J Reprod Med; 1984 Mar; 29(3):193-6. PubMed ID: 6233421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naloxone does not interfere with the dopamine-induced decrease in gonadotropin secretion in women with polycystic ovarian disease.
    Paradisi R; Margrini O; Venturoli S; Fabbri R; Porcu E; Stanzani L; Flamigni C
    Horm Metab Res; 1985 Jan; 17(1):29-31. PubMed ID: 3917966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid peptides in pseudocyesis.
    Devane GW; Vera MI; Buhi WC; Kalra PS
    Obstet Gynecol; 1985 Feb; 65(2):183-8. PubMed ID: 3918282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for altered catecholamine metabolism in polycystic ovary syndrome.
    Shoupe D; Lobo RA
    Am J Obstet Gynecol; 1984 Nov; 150(5 Pt 1):566-71. PubMed ID: 6437227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hyperprolactinemic polycystic ovary syndrome may not be an distinct entity.
    Corenblum B; Taylor PJ
    Fertil Steril; 1982 Nov; 38(5):549-52. PubMed ID: 6813147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constancy of opioid control of luteinizing hormone in different pathophysiological states.
    Lightman SL; Jacobs HS; Maguire AK; McGarrick G; Jeffcoate SL
    J Clin Endocrinol Metab; 1981 Jun; 52(6):1260-3. PubMed ID: 6785301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome.
    Quigley ME; Rakoff JS; Yen SS
    J Clin Endocrinol Metab; 1981 Feb; 52(2):231-4. PubMed ID: 7462389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A longitudinal study on the prognosis of ovulatory disturbance in teenage patients with high LH and normal FSH serum levels].
    Kimura K; Minakami H; Tamada T
    Nihon Naibunpi Gakkai Zasshi; 1988 Oct; 64(10):1088-101. PubMed ID: 3145220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
    J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of bromocriptine on endocrine environment in the polycystic ovary syndrome].
    Huang HJ; Ishimaru T; Yamabe T
    Nihon Naibunpi Gakkai Zasshi; 1988 Apr; 64(4):265-78. PubMed ID: 3136040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further evidence against dopamine deficiency as the cause of inappropriate gonadotropin secretion in patients with polycystic ovary syndrome.
    Rosen GF; Lobo RA
    J Clin Endocrinol Metab; 1987 Nov; 65(5):891-5. PubMed ID: 3117832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.